Trial Profile
A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2023
Price :
$35
*
At a glance
- Drugs MRX-2843 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Meryx
- 10 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Jul 2024.
- 21 Aug 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2023.